Oruka Therapeutics (NASDAQ:ORKA) Sets New 1-Year High on Strong Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) hit a new 52-week high during mid-day trading on Friday following a better than expected earnings announcement. The stock traded as high as $38.75 and last traded at $38.6030, with a volume of 220537 shares traded. The stock had previously closed at $31.99.

The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ORKA. Piper Sandler started coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 price objective on the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. UBS Group initiated coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus increased their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.67.

Insider Activity

In other news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares of the company’s stock, valued at $1,101,162.66. This trade represents a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 21,000 shares of company stock valued at $663,530 over the last ninety days. Company insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in Oruka Therapeutics during the second quarter worth $28,000. Ameritas Investment Partners Inc. bought a new position in shares of Oruka Therapeutics in the second quarter valued at about $31,000. BNP Paribas Financial Markets lifted its stake in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth about $37,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

The firm has a market cap of $1.94 billion, a P/E ratio of -21.51 and a beta of -0.38. The firm’s fifty day moving average is $32.92 and its 200 day moving average is $27.59.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.